ID CP17A_MESAU Reviewed; 511 AA. AC P70687; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1997, sequence version 1. DT 02-SEP-2026, entry version 129. DE RecName: Full=Steroid 17-alpha-hydroxylase/17,20 lyase; DE EC=1.14.14.19 {ECO:0000250|UniProtKB:P05093}; DE AltName: Full=17-alpha-hydroxyprogesterone aldolase; DE EC=1.14.14.32 {ECO:0000250|UniProtKB:P05093}; DE AltName: Full=CYPXVII; DE AltName: Full=Cytochrome P450 17A1; DE AltName: Full=Cytochrome P450-C17; DE Short=Cytochrome P450c17; DE AltName: Full=Steroid 17-alpha-monooxygenase; GN Name=CYP17A1; Synonyms=CYP17; OS Mesocricetus auratus (Golden hamster). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; OC Cricetidae; Cricetinae; Mesocricetus. OX NCBI_TaxID=10036; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Adrenal gland; RX PubMed=8597469; DOI=10.1111/j.1749-6632.1995.tb17390.x-i1; RA Cloutier M., Fleury A., Courtemanche J., Ducharme L., Mason J.I., RA Lehoux J.-G.; RT "Cloning and expression of hamster adrenal cytochrome P450C17 cDNA."; RL Ann. N. Y. Acad. Sci. 774:294-296(1995). CC -!- FUNCTION: A cytochrome P450 monooxygenase involved in corticoid and CC androgen biosynthesis. Catalyzes 17-alpha hydroxylation of C21 CC steroids, which is common for both pathways. A second oxidative step, CC required only for androgen synthesis, involves an acyl-carbon cleavage. CC The 17-alpha hydroxy intermediates, as part of adrenal glucocorticoids CC biosynthesis pathway, are precursors of cortisol. Hydroxylates steroid CC hormones, pregnenolone and progesterone to form 17-alpha hydroxy CC metabolites, followed by the cleavage of the C17-C20 bond to form C19 CC steroids, dehydroepiandrosterone (DHEA) and androstenedione. Has 16- CC alpha hydroxylase activity. Catalyzes 16-alpha hydroxylation of 17- CC alpha hydroxy pregnenolone, followed by the cleavage of the C17-C20 CC bond to form 16-alpha-hydroxy DHEA. Also 16-alpha hydroxylates CC androgens, relevant for estriol synthesis. Mechanistically, uses CC molecular oxygen inserting one oxygen atom into a substrate, and CC reducing the second into a water molecule, with two electrons provided CC by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein CC reductase). {ECO:0000250|UniProtKB:P05093}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a C21-steroid + reduced [NADPH--hemoprotein reductase] + O2 = CC a 17alpha-hydroxy-C21-steroid + oxidized [NADPH--hemoprotein CC reductase] + H2O + H(+); Xref=Rhea:RHEA:65760, Rhea:RHEA-COMP:11964, CC Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, CC ChEBI:CHEBI:61313, ChEBI:CHEBI:138141; EC=1.14.14.19; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:65761; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC -!- CATALYTIC ACTIVITY: CC Reaction=progesterone + reduced [NADPH--hemoprotein reductase] + O2 = CC 17alpha-hydroxyprogesterone + oxidized [NADPH--hemoprotein reductase] CC + H2O + H(+); Xref=Rhea:RHEA:46308, Rhea:RHEA-COMP:11964, Rhea:RHEA- CC COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:17026, ChEBI:CHEBI:17252, ChEBI:CHEBI:57618, CC ChEBI:CHEBI:58210; EC=1.14.14.19; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46309; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC -!- CATALYTIC ACTIVITY: CC Reaction=pregnenolone + reduced [NADPH--hemoprotein reductase] + O2 = CC 17alpha-hydroxypregnenolone + oxidized [NADPH--hemoprotein reductase] CC + H2O + H(+); Xref=Rhea:RHEA:50236, Rhea:RHEA-COMP:11964, Rhea:RHEA- CC COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:16581, ChEBI:CHEBI:28750, ChEBI:CHEBI:57618, CC ChEBI:CHEBI:58210; EC=1.14.14.19; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50237; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC -!- CATALYTIC ACTIVITY: CC Reaction=17alpha-hydroxyprogesterone + reduced [NADPH--hemoprotein CC reductase] + O2 = androst-4-ene-3,17-dione + acetate + oxidized CC [NADPH--hemoprotein reductase] + H2O + 2 H(+); Xref=Rhea:RHEA:14753, CC Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16422, CC ChEBI:CHEBI:17252, ChEBI:CHEBI:30089, ChEBI:CHEBI:57618, CC ChEBI:CHEBI:58210; EC=1.14.14.32; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:14754; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC -!- CATALYTIC ACTIVITY: CC Reaction=17alpha-hydroxyprogesterone + reduced [NADPH--hemoprotein CC reductase] + O2 = 16alpha,17alpha-dihydroxyprogesterone + oxidized CC [NADPH--hemoprotein reductase] + H2O + H(+); Xref=Rhea:RHEA:53216, CC Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:763, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:17252, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53217; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC -!- CATALYTIC ACTIVITY: CC Reaction=16alpha,17alpha-dihydroxyprogesterone + reduced CC [NADPH--hemoprotein reductase] + O2 = 6beta,16alpha,17alpha- CC trihydroxyprogesterone + oxidized [NADPH--hemoprotein reductase] + CC H2O + H(+); Xref=Rhea:RHEA:53220, Rhea:RHEA-COMP:11964, Rhea:RHEA- CC COMP:11965, ChEBI:CHEBI:763, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, CC ChEBI:CHEBI:137046; Evidence={ECO:0000250|UniProtKB:P05093}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53221; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC -!- CATALYTIC ACTIVITY: CC Reaction=17alpha-hydroxypregnenolone + reduced [NADPH--hemoprotein CC reductase] + O2 = 3beta-hydroxyandrost-5-en-17-one + acetate + CC oxidized [NADPH--hemoprotein reductase] + H2O + 2 H(+); CC Xref=Rhea:RHEA:50244, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:28689, ChEBI:CHEBI:28750, ChEBI:CHEBI:30089, CC ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; EC=1.14.14.32; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50245; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC -!- CATALYTIC ACTIVITY: CC Reaction=16alpha,17alpha-dihydroxypregnenolone + reduced CC [NADPH--hemoprotein reductase] + O2 = 3beta,16alpha-dihydroxy- CC androst-5-en-17-one + acetate + oxidized [NADPH--hemoprotein CC reductase] + H2O + 2 H(+); Xref=Rhea:RHEA:53224, Rhea:RHEA- CC COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:27771, CC ChEBI:CHEBI:30089, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, CC ChEBI:CHEBI:137049; Evidence={ECO:0000250|UniProtKB:P05093}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53225; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC -!- CATALYTIC ACTIVITY: CC Reaction=3beta-hydroxyandrost-5-en-17-one + reduced [NADPH--hemoprotein CC reductase] + O2 = 3beta,16alpha-dihydroxy-androst-5-en-17-one + CC oxidized [NADPH--hemoprotein reductase] + H2O + H(+); CC Xref=Rhea:RHEA:47220, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:27771, ChEBI:CHEBI:28689, ChEBI:CHEBI:57618, CC ChEBI:CHEBI:58210; Evidence={ECO:0000250|UniProtKB:P05093}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47221; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC -!- CATALYTIC ACTIVITY: CC Reaction=androst-4-ene-3,17-dione + reduced [NADPH--hemoprotein CC reductase] + O2 = 16alpha-hydroxyandrost-4-ene-3,17-dione + oxidized CC [NADPH--hemoprotein reductase] + H2O + H(+); Xref=Rhea:RHEA:53228, CC Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16422, CC ChEBI:CHEBI:27582, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53229; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC -!- COFACTOR: CC Name=heme; Xref=ChEBI:CHEBI:30413; CC Evidence={ECO:0000250|UniProtKB:P05093}; CC -!- ACTIVITY REGULATION: Regulated predominantly by intracellular cAMP CC levels. The 17,20-lyase activity is stimulated by cytochrome b5, which CC acts as an allosteric effector increasing the Vmax of the lyase CC activity. {ECO:0000250|UniProtKB:P05093}. CC -!- PATHWAY: Steroid hormone biosynthesis. {ECO:0000250|UniProtKB:P05093}. CC -!- PATHWAY: Steroid biosynthesis; glucocorticoid biosynthesis. CC {ECO:0000250|UniProtKB:P05093}. CC -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane CC {ECO:0000250|UniProtKB:P05093}. Microsome membrane CC {ECO:0000250|UniProtKB:P05093}. CC -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U66494; AAB07494.1; -; mRNA. DR RefSeq; NP_001268860.1; NM_001281931.1. DR SMR; P70687; -. DR STRING; 10036.ENSMAUP00000015990; -. DR GeneID; 101831170; -. DR KEGG; maua:101831170; -. DR CTD; 1586; -. DR eggNOG; KOG0156; Eukaryota. DR OrthoDB; 1470350at2759; -. DR UniPathway; UPA00788; -. DR CDD; cd20673; CYP17A1; 1. DR FunFam; 1.10.630.10:FF:000002; Cytochrome P450 1A1; 1. DR Gene3D; 1.10.630.10; Cytochrome P450; 1. DR InterPro; IPR001128; Cyt_P450. DR InterPro; IPR017972; Cyt_P450_CS. DR InterPro; IPR002401; Cyt_P450_E_grp-I. DR InterPro; IPR036396; Cyt_P450_sf. DR PANTHER; PTHR24289; STEROID 17-ALPHA-HYDROXYLASE/17,20 LYASE; 1. DR PANTHER; PTHR24289:SF13; STEROID 17-ALPHA-HYDROXYLASE_17,20 LYASE; 1. DR Pfam; PF00067; p450; 1. DR PRINTS; PR00463; EP450I. DR PRINTS; PR00385; P450. DR SUPFAM; SSF48264; Cytochrome P450; 1. DR PROSITE; PS00086; CYTOCHROME_P450; 1. DR GO; GO:0005789; C:endoplasmic reticulum membrane; ISS:UniProtKB. DR GO; GO:0020037; F:heme binding; ISS:UniProtKB. DR GO; GO:0005506; F:iron ion binding; IEA:InterPro. DR GO; GO:0004508; F:steroid 17-alpha-monooxygenase activity; ISS:UniProtKB. DR GO; GO:0006704; P:glucocorticoid biosynthetic process; IEA:UniProtKB-UniPathway. DR GO; GO:0042446; P:hormone biosynthetic process; ISS:UniProtKB. DR GO; GO:0042448; P:progesterone metabolic process; ISS:UniProtKB. DR GO; GO:0008202; P:steroid metabolic process; ISS:UniProtKB. DR Proteomes; UP000886700; Unplaced. DR AlphaFoldDB; P70687; -. PE 2: Evidence at transcript level; KW Endoplasmic reticulum; Heme; Iron; Lipid metabolism; Lyase; Membrane; KW Metal-binding; Microsome; Monooxygenase; Oxidoreductase; KW Reference proteome; Steroidogenesis. FT CHAIN 1..511 FT /note="Steroid 17-alpha-hydroxylase/17,20 lyase" FT /id="PRO_0000051934" FT BINDING 442 FT /ligand="heme" FT /ligand_id="ChEBI:CHEBI:30413" FT /ligand_part="Fe" FT /ligand_part_id="ChEBI:CHEBI:18248" FT /note="axial binding residue" FT /evidence="ECO:0000250" SQ SEQUENCE 511 AA; 57459 MW; 896E776A7457546C CRC64; MWELVALLLL TLAYFFWSKS KTCGAKSPKS LPFLPLVGSL PFIPRHGHPH VNFFKLQEKY GPIYSLRLGS TTTVIIGQYQ LAKEVLVKKG KEFSGRPHMV TLGLLSDQGK GIAFADSGGS WQLHRKLALS SFALFRDGNQ KLEKIICQKA SSLCDFLLTH NEESIDLSEP IFNSITNIIC IICFGISYEN RDPILATIKS FTEGILNSLG NDHLVDIFPW LTIFPNKTVD MIKKNVKIRD EVLSGILEKC KEKFNSDSIS SLMDLLIQAK TNADNNNTSE GQGSNAFSDM HILATIADIF GAGIETTASV LSWIIAFLLH NPEVKKKIQK EIDQNIGFSR TPTFNDRNHL LMLEATIREV LRIRPVAPML IPHRANSDMS IGEFSIPKFT PVIINLWALH HSEKEWDQPD RFMPERFLDP TGSHLITPSL SYLPFGAGAR SCIGEVLARQ ELFLFMAHLL QRFDLDVPDD EQPPCLKGNA NVVFLIDPFK VKITVRQAWK DAQAEVNTWR P //